Ernexa Therapeutics Inc. Stockholders Equity

• Ernexa Therapeutics Inc. showed an increase of +41.2% in Stockholders Equity from 2024 to 2025.
• This data is from Ernexa Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2016: $4.07 million | Q1 2017: $5.83 million | Q2 2017: $6.03 million | Q3 2017: $6.06 million | Q1 2018: $5.20 million | Q2 2018: $6.54 million | Q3 2018: $6.90 million | Q1 2019: $6.69 million | Q2 2019: $6.67 million | Q3 2019: $6.35 million | Q1 2020: $9.06 million | Q2 2020: $11.76 million | Q3 2020: $9.76 million | Q1 2021: $14.00 million | Q2 2021: $53.60 million | Q3 2021: $31.53 million | Q1 2022: $17.31 million | Q2 2022: $14.78 million | Q3 2022: $8.81 million | Q1 2023: $7.38 million | Q2 2023: $3.87 million | Q3 2023: $3.56 million | Q1 2024: -$3.41 million | Q2 2024: -$8.53 million | Q3 2024: -$45.39 million | Q1 2025: -$5.95 million | Q2 2025: $4.44 million | Q3 2025: $3.57 million.
• Over the full 17 years of available data (2009 to 2025), Ernexa Therapeutics Inc.'s Stockholders Equity has declined by 74.5%.
• Historical annual values: Fiscal year 2025: $2.40 million | Fiscal year 2024: $1.70 million | Fiscal year 2023: $2.23 million | Fiscal year 2022: $12.11 million | Fiscal year 2021: $25.50 million | Fiscal year 2020: $7.66 million | Fiscal year 2019: $9.74 million | Fiscal year 2018: $6.92 million | Fiscal year 2017: $5.54 million | Fiscal year 2016: $4.07 million | Fiscal year 2015: $3.85 million | Fiscal year 2014: $10.92 million | Fiscal year 2013: $9.20 million | Fiscal year 2012: $7.89 million | Fiscal year 2011: $6.35 million | Fiscal year 2010: $9.46 million | Fiscal year 2009: $9.42 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026